High-Load Compound A Tablets With Fluidized Bed Granulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Compound A exhibits poor powder flowability and adhesion during granulation and tableting processes, leading to difficulties in formulating high-content tablets, which are prone to sticking and defects.
Innovation Solution
A pharmaceutical composition is developed by spraying a binding solution containing Compound A and a binder onto a powder in a fluidized bed granulator, followed by granulation and tableting, using specific ratios and additives like calcium carmellose, hydroxypropyl cellulose, and lactose to improve flowability and reduce sticking.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound A is used as an active ingredient in pharmaceutical formulation, then MCR activation effect is improved, but powder flowability deteriorates
Solution Approach 1:
The patent uses granulation technology as an intermediary process to transform the problematic powder properties of Compound A. By converting the powder into granulated form through fluidized bed granulation, the invention mediates between maintaining the active ingredient's efficacy and improving its physical handling properties for formulation.
Solution Approach 2:
The invention changes the physical parameters of Compound A by converting it from fine powder to granulated form. This parameter change in particle morphology and size distribution improves flowability and reduces adhesion while preserving the chemical integrity and biological activity of the compound.
2Volume of moving object
If Compound A is used in high content rate to reduce tablet size, then compact form is improved, but adhesion to container during granulation worsens
Solution Approach 1:
The invention changes the physical state and particle characteristics of Compound A through granulation, transforming it from a form that adheres to containers into granulated material with improved flow and reduced adhesion properties, enabling high-content formulation without sticking issues.
Solution Approach 2:
The granulation process acts as an intermediary that enables high content rates of Compound A in tablets. By introducing this intermediate processing step, the invention resolves the conflict between achieving compact tablet size through high drug content and avoiding adhesion problems during manufacturing.
3Volume of moving object
If Compound A is used in high content rate, then tablet compactness is improved, but sticking during tableting process worsens
Solution Approach 1:
The invention applies preliminary granulation action before the tableting process. By pre-forming granulated material with improved physical properties, the invention prevents sticking issues that would otherwise occur during subsequent tableting of high-content Compound A formulations.
Solution Approach 2:
The granulation process changes the physical parameters of Compound A, creating granulated material with optimal moisture content, particle size distribution, and surface characteristics that prevent sticking during tableting while enabling high drug content for compact tablets.
4Device complexity
If conventional granulation method is used, then formulation process is simplified, but manufacturing precision deteriorates due to poor flowability and adhesion
Solution Approach 1:
The patent introduces fluidized bed granulation as an intermediary processing step that improves manufacturing precision. This intermediate granulation stage creates material with consistent physical properties, enabling more precise and reliable subsequent tableting operations despite the added process step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables efficient production of high-content tablets with reduced defects, maintaining drug release properties and compact form, while overcoming adhesion and sticking issues.
Implementation Method 1
spraying a binding solution containing Compound A or the like and a binder onto a powder in a container of a fluidized bed granulator to perform granulation
Data Source
AI summary
A pharmaceutical composition containing 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid (Compound A) or a pharmaceutically acceptable salt or co-crystal thereof as an active ingredient, wherein a content of Compound A is 30% by weight or more based on a total weight of the pharmaceutical composition. The pharmaceutical composition is preferably obtained using a production method that includes a granulation step of obtaining a granulated product by spraying a binding solution containing Compound A or a pharmaceutically acceptable salt or co-crystal thereof and a binder onto a powder containing Compound A or a pharmaceutically acceptable salt or co-crystal thereof in a fluidized bed granulator